Iterion Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $7.1M

  • Investors
  • 12

Iterion Therapeutics General Information

Description

Developer of novel targeted cancer therapeutics and a first-in-class small molecule inhibitor designed to treat advanced hepatocellular carcinoma and other Wnt-driven tumors for patients globally. The company utilizes its proprietary lead product, Tegavivint, to selectively degrade nuclear β-catenin and target TBL1 without the toxicities associated with traditional Wnt inhibitors, enabling oncology researchers, clinicians, and pharmaceutical partners to advance clinical trials, provide targeted therapies for previously undruggable cancer pathways, and improve durable disease control in heavily pre-treated oncology patients.

Contact Information

Formerly Known As
Beta Cat Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7255 Helix Park Avenue
  • Houston, TX 77030
  • United States
+1 (317)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 7255 Helix Park Avenue
  • Houston, TX 77030
  • United States
+1 (317)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Iterion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Grant 19-Nov-2025 $7.1M Completed Clinical Trials - Phase 2
11. Grant 16-Feb-2022 Completed Clinical Trials - Phase 2
10. Later Stage VC (Series B1) 16-Feb-2021 Completed Clinical Trials - Phase 2
9. Debt - PPP 11-Apr-2020 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B) 05-Dec-2018 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series A1) 18-Dec-2017 Completed Startup
6. Accelerator/Incubator 02-Mar-2016 Completed Startup
5. Early Stage VC (Series A) 18-Jun-2015 Completed Startup
4. Angel (individual) 07-Jul-2014 $500K $775K Completed Startup
3. Grant 19-Feb-2014 $15.9M $275K Completed Startup
To view Iterion Therapeutics’s complete valuation and funding history, request access »

Iterion Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B1
Series B
Series A2 5,236,054 $0.001000 8% $0.46 $0.46 1x $0.46 8.27%
Series A1 4,369,655 $0.001000 8% $0.38 $0.38 1x $0.38 6.91%
To view Iterion Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Iterion Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel targeted cancer therapeutics and a first-in-class small molecule inhibitor designed to treat advanced
Drug Discovery
Houston, TX
16 As of 2026

San Diego, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Iterion Therapeutics Competitors (85)

One of Iterion Therapeutics’s 85 competitors is Dauntless Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dauntless Pharmaceuticals Formerly VC-backed San Diego, CA
Compass Therapeutics Formerly VC-backed Boston, MA
PDX Pharmaceuticals Venture Capital-Backed Portland, OR
Apollomics Formerly VC-backed Foster City, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 85 competitors. Get the full list »

Iterion Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Iterion Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Clarevia Ventures Venture Capital Minority
Green Park & Golf Ventures Venture Capital Minority
Lumira Ventures Venture Capital Minority
Portal Innovations Venture Capital Minority
Viva BioInnovator Accelerator/Incubator Minority
You’re viewing 5 of 12 investors. Get the full list »

Iterion Therapeutics FAQs

  • When was Iterion Therapeutics founded?

    Iterion Therapeutics was founded in 2010.

  • Where is Iterion Therapeutics headquartered?

    Iterion Therapeutics is headquartered in Houston, TX.

  • What is the size of Iterion Therapeutics?

    Iterion Therapeutics has 16 total employees.

  • What industry is Iterion Therapeutics in?

    Iterion Therapeutics’s primary industry is Drug Discovery.

  • Is Iterion Therapeutics a private or public company?

    Iterion Therapeutics is a Private company.

  • What is Iterion Therapeutics’s current revenue?

    The current revenue for Iterion Therapeutics is .

  • How much funding has Iterion Therapeutics raised over time?

    Iterion Therapeutics has raised $27.2M.

  • Who are Iterion Therapeutics’s investors?

    Clarevia Ventures, Green Park & Golf Ventures, Lumira Ventures, Portal Innovations, and Viva BioInnovator are 5 of 12 investors who have invested in Iterion Therapeutics.

  • Who are Iterion Therapeutics’s competitors?

    Dauntless Pharmaceuticals, Compass Therapeutics, PDX Pharmaceuticals, Apollomics, and Adaptimmune Therapeutics are some of the 85 competitors of Iterion Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process